.svg)
March 26, 2026 – Rockville, Md. – Psomagen is thrilled to announce the arrival of our newest single-cell platform, the Cellanome™ R3200. This instrument makes use of Cellanome’s innovative micro-3D-printed CellCage™ technology to isolate single cells or ensembles for extended cultures of cells of interest.
This platform is a promising option for researchers in complex fields such as immuno-oncology, oncology, and neurobiology. The platform opens a new area in single cell science: Cellanome is the only platform that allows researchers to capture morphology, phenotypic insights, and single-cell RNAseq on the same exact cells! This revolutionary tool uses AI-designed permeable CellCage™ Enclosures to isolate single cells, but still allows antibodies and drugs to flow directly onto the individual cells.
Cellanome adds to Psomagen’s Single Cell & Spatial Biology Center of Excellence, offering state-of-the-art tools from 10x Genomics, OmicInsight, and NanoString/Bruker. “A key goal for Psomagen is to offer a portfolio of instruments that enhance and complement each other,” says Dr. Su Hong, Psomagen CEO. “The addition of Cellanome’s R3200 platform offers real-time cellular imaging and behavioral insights not possible on other instruments. We’re very excited to see what our customers will discover with this additional level of data delivery.”
About Psomagen
Psomagen, Inc., formerly Macrogen U.S.A., is a North American integrative omics solutions and contract laboratory services provider. The company makes cutting-edge technology and data analysis accessible to the academic, pharma, biotech and clinical markets. With both CLIA-certified and CAP-accredited facilities, its team delivers the highest-quality multiomics data using best-in-class DNA, RNA, and protein analysis systems. In conjunction with its bioinformatics capabilities, Psomagen offers a path to insights that is both simple and affordable. Learn more at psomagen.com.
